Pfizer Stock Prediction and Forecast [PFE]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 13 Sept 2025, 03:13 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Pfizer Stock Prediction and Forecast [PFE]](https://i.ytimg.com/vi/dpOtgaPjieg/hqdefault.jpg)
AI-generated source summary
The analysis suggests that Pfizer (PFE) is facing bearish conditions. Since September 12, 2025, the system ranks it as a sell candidate with a score of -2.6. The stock is at the lower end of a horizontal trend. Breaking below $23.44 would signal a strong sell, whereas the anticipated 3-month change is an approximate 1.18% change. The expected 12-month change is -15.82%, varying between -$31.11 and -$9.34. The latest daily data shows a -3.98% decrease to $23.87, and the weekly volatility is 2.03%, with a very low-risk assessment. Trading volume also increased significantly. The latest analyst ratings were neutral and the insider power for the stock is 41.889. There are sell signals from both short and long term Moving Averages. Resistance is at $24.57 and $24.67. There is no stop-loss suggestion.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
